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Abstract
Background
The majority of new tuberculosis cases emerging every year occur in low and middle-
income countries where public health systems are often characterised by weak infrastruc-
ture and inadequate resources. This study investigates healthcare seeking behaviour,
knowledge and treatment of tuberculosis patients in Myanmar—which is facing an acute
drug-resistant tuberculosis epidemic—and identifies factors that may increase the risk of
emergence of drug-resistant tuberculosis.
Methods
We randomly selected adult smear-positive pulmonary tuberculosis patients diagnosed
between September 2014 and March 2015 at ten public township health centres in Yangon,
the largest city in Myanmar. Data on patients’ healthcare seeking behaviour, treatment at
the township health centres, co-morbidities and knowledge was collected through patient
interviews and extraction from hospital records. A retrospective descriptive cross-sectional
analysis was conducted.
Results
Of 404 TB patients selected to participate in the study, 11 had died since diagnosis, resulting
in 393 patients being included in the final analysis. Results indicate that a high proportion of
patients (16%; 95% CI = 13–20) did not have a treatment supporter assigned to improve
adherence to medication, with men being more likely to have no treatment supporter
assigned. Use of private healthcare providers was very common; 59% (54–64) and 30.3%
(25.9–35.0) of patients reported first seeking care at private clinics and pharmacies respec-
tively. We found that 8% (6–11) of tuberculosis patients had confirmed diabetes. Most
patients had some knowledge about tuberculosis transmission and the consequences of
missing treatment. However, 5% (3–8) stated that they miss taking tuberculosis medicines
at least weekly, and patients with no knowledge of consequences of missing treatment were
more likely to miss doses.
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Conclusions
This study analysed healthcare seeking behaviour and treatment related practices of tuber-
culosis patients being managed under operational conditions in a fragile health system.
Findings indicate that ensuring that treatment adherence support is arranged for all patients,
monitoring of response to treatment among the high proportion of tuberculosis patients with
diabetes and engagement with private healthcare providers could be strategies addressed
to reduce the risk of emergence of drug-resistant tuberculosis.
Background
Despite decades of investment, tuberculosis (TB) is proving to be challenging to control for
numerous reasons: lack of timely access to quality diagnostic and treatment services for vul-
nerable populations, a long (minimum six month) duration of treatment which places a great
burden on patients and the health system, and dominance of private healthcare providers that
often do not follow TB management guidelines in numerous high TB burden countries [1].
These factors have contributed to the emergence and spread of drug-resistant TB, which is
threatening to reverse progress made in TB control in recent decades; globally, 21% (15–28%)
of previously treated cases and 4% (3–5%) of new cases are estimated to have TB that is resis-
tant to at least the two major anti-tuberculosis drugs, isoniazid and rifampicin [2].
The majority of the 480,000 new MDR-TB cases and approximately 10 million new TB
cases emerging every year occur in low and middle-income countries. Health systems in these
countries are often characterised by weak infrastructure and inadequate resources (referred to
as fragile health systems) and they are therefore poorly equipped to cope with the complexities
and expenses of diagnosing and managing the disease [2]. Unfortunately, countries that are
least able to cope with a high MDR-TB burden are often those where the health system strug-
gles to effectively treat all TB patients, driving the emergence of drug resistance [3, 4].
Myanmar is a low-income country whose fragile health system—which is receiving external
support for human resource capacity building, medical equipment and programme implemen-
tation—has to cope with very high TB and MDR-TB rates [5]. The TB prevalence rate is 525
cases per 100,000 population—more than four times higher than the global average. An esti-
mated 180,000 new TB cases emerge every year [5]. Among newly diagnosed cases, it is esti-
mated that 5% of previously untreated and 27% of previously treated patients have MDR-TB;
this is considerably higher than other countries in South East Asia, such as Cambodia (1.4%
and 11% respectively) and Thailand (2% and 19% respectively) [2].
An understanding of patient behaviour before and during TB treatment in the context of a
fragile health system is important as it may indicate factors associated with the potential gener-
ation of MDR-TB [6]. This study investigates healthcare seeking behaviour, knowledge and
treatment of tuberculosis patients under operational conditions in Myanmar’s resource-con-
strained public health system.
Methods
Study setting
Health services in Yangon, which is the country’s main urban centre with a population of 7.4
million, are provided by a combination of the public and private sector. Some private health-
care providers, such as the Myanmar Medical Association (MMA) and Population Services
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International (PSI) linked SUN clinics, are affiliated with the National Tuberculosis Pro-
gramme (NTP) to provide standardised TB services. The majority of private healthcare provid-
ers are, however, unregulated by any government bodies and include small clinics, hospitals,
pharmacies and informal drug sellers. The national Ministry of Health is responsible for the
management of the public sector services and the NTP oversees TB control activities. TB con-
trol activities are implemented through Yangon’s Township Health Departments (THDs),
which function as the main health facilities providing primary health care services and as the
first point of accessing services for TB diagnosis, case registration and treatment provision.
These services are provided without charge to patients. Our study was conducted in ten THDs
across Yangon, identified by the NTP as having a particularly high MDR-TB burden (defined
as having 2–4 new cases diagnosed per month). These THDs were located in the following
townships: Hlaing, Hlaing Thar Yar, Insein, Mayangone, Mingaladon, North Dagon, North
Okkalapa, Shwe Pyi Thar, South Okkalapa and Thingangyun.
Participants
We randomly selected TB patients for inclusion rather than including all TB cases because the
number of new cases diagnosed every month was very large, and we wanted to recruit patients
over a minimum six-month period to obtain a representative sample. Random selection was
weighted according to the MDR-TB burden in each study township, such that a proportionally
larger number of TB patients would be selected from townships with higher MDR-TB patient
numbers. Our exclusion criteria were: age<18 years; known pregnancy at time of data collec-
tion; residence outside Yangon or in Yangon <3 months; and extrapulmonary TB only.
Data collection, management and analysis
After confirming eligibility and willingness to participate we retrospectively collected data
from TB patients three months after they had been diagnosed. A three month period post diag-
nosis was selected to achieve a balance between optimal recall of behaviour in the period prior
to diagnosis and to allow information about adherence to treatment in the initial phase of
treatment to be collected. A data collector fluent in the local language and trained to adminis-
ter the questionnaire was assigned to each township. Using Caminero’s classification of risk
factors for MDR-TB [4] as a starting point, we designed and piloted data collection tools for
capturing information on patient and health system variables. Two structured questionnaires
were filled out for each participant. The first extracted data from townships labs, TB registers
at the township health centres and patients’ individual treatment cards. The second question-
naire was based on primary data collected during face-to-face interviews with patients at their
homes.
Data was collected using paper-based questionnaires, checked manually by the study super-
visor and then entered into Epidata (Version 3.1, The EpiData Association, Odense,8.
Denmark). The Epidata file had built-in checks to alert the data entry manager if out of
range values were entered. Blinded double entry was conducted by the study supervisor on a
monthly basis for 20% of all questionnaires (randomly selected). If any errors were identified,
all questionnaires from the same data collector were checked and the data collector re-trained
on the relevant questions if required.
Raw data was transferred to Stata (version 10, Stata Corporation, College Station, TX) for
management and statistical analysis. We conducted a descriptive analysis and report numbers
and percentages for the categorical variables we analysed. Where indicated in the results sec-
tion, we conducted additional analysis of association between risk factors and specific patient
characteristics using the Pearson chi-squared test.
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Ethics
Ethical clearance was obtained from LSHTM Research Ethics Committee, the FHI 360 Protec-
tion of Human Subjects Committee and the Myanmar Ministry of Health. Written informed
consent was sought from all participants.
Results
Between Sept 2014 and March 2015, 1691 new eligible smear-positive pulmonary TB patients
were diagnosed at the ten study THDs. We excluded 19 patients owing to missing information
on age and sex, leaving a sampling frame of 1672. We randomly selected 404 TB patients to
participate in the study, of which 11 had died since diagnosis, resulting in 393 patients being
included in the final analysis (S1 dataset).
Demographic and socioeconomic characteristics of the study population are summarised
in Table 1. Health system related factors related to healthcare seeking behaviour and treatment
support are summarised in Table 2. Our results indicate high use of (unregulated) private
healthcare providers that do not offer free, standardised diagnosis and treatment for TB; in
terms of actual healthcare seeking behaviour reported, 67.2% (62.4–71.7) of TB patients visited
a private allopathic healthcare provider in the past two years. In contrast, reported use of non-
allopathic healthcare providers (traditional healers) in the past two years was relatively low in
Yangon at 4.1% (2.5–6.6) in the past two years. Our analysis of stated preferences for health-
care seeking revealed that over 90% of TB patients’ first choice is to seek care at a private health
facility. Among private health facilities chosen for the first healthcare seeking visit, clinics
(59.3% [54.3–64.1]) and pharmacies (30.3% [25.9–35.0]) were the two most commonly cited.
Only 4.6% (2.9–7.2) of patients stated that a government facility would be their first choice.
Once TB patients had started treatment through the NTP, less than 7% continued to seek care
for TB symptoms at a private hospital, clinic or pharmacy.
While health facilities allocated a family member to support treatment for the majority of
TB patients (78.6% [74.3–82.4]), 16% (12.7–20.0) reported that they did not have treatment
supporters assigned to monitor and support their adherence to TB medication. Further analy-
sis indicated that male patients were less likely to be assigned a treatment supporter, with
18.7% (14.0–23.3) of men and 10.4% (5.0–15.8) of women (p = 0.038) being allocated no treat-
ment supporter by the health facility. Other factors such as the patient’s age, ethnicity and mar-
ital status were not found to be associated with assignment of a treatment supporter (not
shown in tables).
As summarised in Table 3, most patients (75.1% [70.5–79.1]) had some knowledge about
how TB is transmitted and almost 95% were aware of some negative consequences of missing
TB treatment. Several questions were asked to estimate adherence to treatment, all of which
indicated that approximately 5% of TB patients regularly miss taking drugs. We found that
4.6% (2.9–7.2) of patients stated that they had missed taking treatment in the past 4 days, and
similarly 4.8% (3.1–7.5) stated that they miss taking TB medicines weekly or more often. Over
the past month, 6.7% (4.5–9.6) recalled that missing at least one dose of TB medication. There
was a strong association between knowledge of consequences of missing treatment and missing
treatment more than weekly (not shown in tables); 23.8% (5.6–42.2) of patients who had no
knowledge of consequences of poor adherence to TB treatment reported missing treatment
more than weekly, as compared to 3% (0–5.5) of patients who knew about emergence of drug
resistance and 4% (1.8–6.8) of patients who were aware that symptoms can worsen (p<0.0001).
At the individual level (Table 4), there was a high prevalence of confirmed diabetes (7.9%
[5.6–11.0]) among TB patients. We found that information on HIV status was incomplete as
routine testing of all TB patients was not implemented at THDs.
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Discussion
This study provides new information about healthcare seeking behaviour and management of
TB patients under operational conditions in the context of a resource-limited setting, where
investment and reform are ongoing to try and address the epidemiological challenge of high
rates of TB and MDR-TB. We identified lack of treatment adherence support and high use of
unregulated private healthcare providers as health system related factors potentially driving
the generation of MDR-TB. In terms of patient-level factors, a substantial proportion of TB
Table 1. Demographic and socioeconomic characteristics of TB patients included in the study. * =
private healthcare providers working in partnership with the National TB program
Characteristic Number of
Patients
(N = 393)
Proportion of Patients (95% Confidence
Intervals)
Age
18–24 52 13.2 (10.2–17)
25–34 99 25.2 (21.1–29.7)
35–44 95 24.2 (20.2–28.7)
45–54 70 17.8 (14.3–21.9)
55–64 45 11.5 (8.6–15.0)
Over 65 32 8.1 (5.8–11.3)
Female Sex 125 31.8 (27.4–36.6)
Ethnic group
Bamar 345 87.8 (84.1–90.7)
Mixed 9 2.3 (1.2–4.4)
Ethnic minority 39 9.9 (7.3–13.3)
Religion
Buddhist 37 94.1 (91.3–96.1)
Christian 7 1.8 (0.8–3.7)
Muslim 14 3.6 (2.1–5.9)
Hindu 2 0.5 (0.1–2.0)
Occupation
Dependent 81 20.6 (16.9–24.9)
Daily wage earner 41 10.4 (7.8–13.9)
Self or privately employed 171 43.5 (38.7–48.5)
Government employee 23 5.9 (3.9–8.7)
Unemployed 62 15.8 (12.5–19.7)
Retired/Other 15 3.8 (2.3–6.2)
Education level
None or less than primary 77 19.6 (15.9–23.8)
Only primary completed 121 30.8 (26.4–35.6)
Only middle school completed 124 31.5 (27.1–36.3)
High school completed or higher 71 18.1 (14.6–22.2)
Healthcare provider used for TB
treatment
National TB Programme 314 79.9 (75.6–83.6)
Myanmar Medical Association * 32 8.1 (5.8–11.3)
Sun Clinic* 45 11.5 (8.6–15.0)
Private hospital 2 0.5 (0.1–2.0)
https://doi.org/10.1371/journal.pone.0177999.t001
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patients (7.9%) had confirmed diabetes, which is associated with a higher risk of poor TB
treatment outcomes [7].
Despite being a central component of the World Health Organization’s TB control strategy,
we found that 16% of patients had no treatment supporter. There is increasing evidence that
direct observation of treatment at a health centre does not improve treatment outcomes and
that a community based treatment supporter is as effective as, or superior to, a health-service
based treatment supporter [8, 9]. In our study setting, in line with other settings with limited
human resources for health service delivery, family members were commonly selected to act as
treatment supporters, which reduces burden on the health system. However, our finding that a
considerable proportion of patients, particularly men, had no treatment supporter assigned to
them indicates that steps required to identify and coach a family or community member to act
as a treatment supporter were not being taken consistently at the public health facilities in our
study. Furthermore, while we sought to include HIV-coinfection in our analysis, we found
Table 2. Healthcare seeking behaviour and treatment support.
Variable Number of
Patients
(N = 393)
Proportion of Patients
(95% Confidence
Intervals)
Preferred (first) health care provider to visit when sick
Private clinic / hospital 233 59.3 (54.3–64.1)
Government run clinic / hospital 18 4.6 (2.9–7.2)
Private pharmacy 119 30.3 (25.9–35.0)
Informal drug seller 11 2.8 (1.6–5.0)
Informal care / traditional healer 2 0.5 (0.1–2.0)
Nobody 10 2.5 (1.4–4.7)
Actual visits to a private doctor in the past 2 years
No 129 32.8 (28.3–37.6)
Yes 264 67.2 (62.4–71.7)
Actual visits to a traditional healer in the past 2 years
No 377 95.9 (93.4–97.5)
Yes 16 4.1 (2.5–6.6)
Visits to additional allopathic healthcare provider after
TB diagnosis by NTP
No 283 72.0 (67.3–76.2)
MMA (NTP affiliated) 36 9.1 (6.7–12.5)
PSI / Sun clinic (NTP affiliated) 46 11.7 (8.9–15.3)
Private clinic 18 4.6 (2.9–7.2)
Private Hospital 6 1.5 (0.7–3.4)
Pharmacy 2 0.5 (0.1–2.0)
Other 1 0.3 (0–1.8)
Missing 1 0.3 (0–1.8)
Visits to traditional healer after TB diagnosis by NTP
No 383 97.5 (95.3–98.6)
Yes 10 2.5 (1.4–4.7)
TB treatment supporter assigned by health facility staff
None assigned 63 16.0 (12.7–20.0)
Household member 309 78.6 (74.3–82.4)
Non-household family member 17 4.4 (2.7–6.9)
Other 4 1.0 (0.4–2.7)
https://doi.org/10.1371/journal.pone.0177999.t002
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that one third of TB patients did not have HIV test results recorded in township registers, and
suggest that routine HIV testing should be considered for all TB patients. We acknowledge,
however, that resource constraints within THDs may be important barriers to ensuring com-
prehensive coverage of HIV testing and treatment supporters.
Our study in Myanmar also provides new information about healthcare seeking behaviour of
TB patients when the private sector is a dominant component of the health system [10]. In this
context, the vast majority (over 90%) of TB patients reported first visiting a private healthcare
facility rather than a public one, which is consistent with, but slightly higher than, rates reported
in other Asian settings [11]. This is despite TB drugs and diagnostic tests being available without
charge at public sector THDs, and no known waiting lists for first-line TB drugs. Use of allo-
pathic health services, rather than traditional healers, was preferred by patients in this urban set-
ting. Evidence from other studies indicates that TB patients prefer to use private health facilities
owing to factors such as convenience, confidentiality and perceived quality of service, although
quality of care is often suboptimal [12–14]. Specifically, for-profit healthcare providers operating
in a setting with limited enforcements of laws to control service quality have been known to
inappropriately dispense antibiotics increasing the risk of antibiotic resistance developing [15,
16]. While we did not investigate regulation of the private health sector or quality of TB care
delivered by private healthcare providers as part of this study, other studies in Myanmar have
Table 3. Knowledge and adherence to treatment.
Variable Number of
Patients
(N = 393)
Proportion of Patients
(95% Confidence
Intervals)
Knowledge of how TB is spread
No 98 24.9 (20.9–29.5)
Yes (airborne/coughing) 295 75.1 (70.5–79.1)
Knowledge of impact of missed treatment
Nothing 21 5.3 (3.5–8.1)
Drug resistance 115 29.3 (25–34)
Symptoms get worse 230 58.5 (53.6–63.3)
Drug resistant and symptoms get worse 27 6.9 (4.7–9.8)
Patients reported missing treatment in last 4 days
No 375 95.4 (92.8–97.1)
Yes 18 4.6 (2.9–7.2)
Patients reported missing treatment in last month
No 366 93.1 (90.2–95.3)
Yes 26 6.6 (4.5–9.6)
Missing 1 0.3 (0–1.8)
How often patient missed taking TB drugs (self
reported)
Never 365 92.9 (89.9–95)
Less than once a week 9 2.3 (1.2–4.4)
More than once a week 19 4.8 (3.1–7.5)
Reasons provided for missing TB drugs
Did not miss taking drugs 365 92.9 (89.9–95)
Forgot 3 0.7 (0.2–2.4)
Ran out / forgot to pick up 7 1.8 (0.8–3.7)
Side effects 5 1.3 (0.5–3)
Other 13 3.3 (1.9–5.6)
https://doi.org/10.1371/journal.pone.0177999.t003
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shown that private allopathic clinics deviate from guidelines including observation of TB treat-
ment [10], formal (written) monitoring of patient progress during treatment [17] and use of
smear-microscopy for diagnosis in patients with symptoms consistent with TB [18].
A small but substantial proportion of patients reported frequently missing treatment; while
overall patient knowledge of consequences of missing treatment was high, we found that the
minority (5%) of patients who were not aware of any consequences of poor adherence to TB
treatment were more likely to report missing treatment more than weekly. We recognise that a
limitation of our study is that we only collected adherence data about the first three months of
treatment, whereas adherence to treatment may worsen in later months. We also recognise the
potential for under-reporting in data based on self-reported information about smoking, alco-
hol consumption and missed treatment.
Conclusion
Our study identifies healthcare seeking and treatment adherence behaviour—as well as co-
morbidities in TB patients—that should be investigated further as potential drivers of drug
resistance. It is optimal from a patient and health system perspective to prevent the emergence
of drug resistance, and this is recognised as the first step to controlling MDR-TB in high preva-
lence countries such as Myanmar [4]. The present study indicates potential strategies that may
be considered to reduce of the risk of MDR-TB, such as introduction of processes at public
health facilities that ensure consistency in assignment of treatment supporters to all TB
patients and engagement with private healthcare providers to avoid inappropriate treatment of
potential TB patients. Further studies evaluating the impact and cost-effectiveness of measures
to prevent generation of drug resistance in patients treated for primary TB in resource-limited
settings are warranted.
Supporting information
S1 Dataset. Dataset of TB patients used for the analysis.
(XLSX)
Table 4. Factors influencing individual patients’ vulnerability.
Variable Number of Patients
(N = 393)
Proportion of Patients
(95% Confidence Intervals)
HIV status
Tested negative 251 63.9 (59–68.5)
Tested positive 13 3.3 (1.9–5.6)
Not tested 129 32.8 (28.3–37.6)
Diabetes Status
Tested negative 298 75.8 (71.3–79.8)
Tested positive 31 7.9 (5.6–11.0)
Not tested 64 16.3 (12.9–20.3)
Alcohol consumption
Never 184 46.8 (41.9–51.8)
Past drinker 175 44.5 (39.7–49.5)
Current drinker 34 8.7 (6.2–11.9)
Smoking
Never 181 46.0 (41.2–51)
Past smoker 174 9.7 (7.1–13)
Current smoker 38 44.3 (39.4–49.2)
https://doi.org/10.1371/journal.pone.0177999.t004
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